RESEARCH

NEXT Lab (Hanyang University) develops APC-targeted nanoparticle platforms that reprogram pathological immune microenvironments and enable next-generation immune therapeutics.

Our research integrates glycan-engineered nanomedicine and nucleic acid delivery to activate antigen-presenting cells, driving effective vaccines and treatments for cancer and inflammatory diseases.

By bridging nanoscience and immunology, we translate precisely engineered biomaterials into practical, immune-based therapies.